InvestorsObserver
×
News Home

Should You Sell Aptose Biosciences Inc (APTO) in Biotechnology Industry?

Tuesday, November 28, 2023 10:14 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Sell Aptose Biosciences Inc (APTO) in Biotechnology Industry?

Aptose Biosciences Inc (APTO) is near the middle in its industry group according to InvestorsObserver. APTO gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Aptose Biosciences Inc gets a 38 rank in the Biotechnology industry. Biotechnology is number 54 out of 148 industries.

Overall Score - 38
APTO has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on APTO!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Aptose Biosciences Inc Stock Today?

Aptose Biosciences Inc (APTO) stock has risen 3.6% while the S&P 500 is lower by -0.18% as of 9:45 AM on Tuesday, Nov 28. APTO is higher by $0.08 from the previous closing price of $2.22 on volume of 1,559 shares. Over the past year the S&P 500 is higher by 14.59% while APTO is lower by -77.45%. APTO lost -$7.87 per share the over the last 12 months. Click Here to get the full Stock Report for Aptose Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App